September 09, 2003

PolyMedica's criminal prosecution firmly on track.

Last week investors bid PolyMedica Corporation's (NASDAQ: PLMD, $52.00) shares up as high as 29.5% above the prior week's close after the company announced that it would continue to capitalize its advertising expenses. Earlier PolyMedica had disclosed that the Securities and Exchange Commission believed that its advertising expenses did not qualify for capitalization. Last week's announcement has no effect on PolyMedica's historical or future cash flow. PolyMedica will merely continue to report lower than actual expenses and inflate its non-cash earnings. Yet PolyMedica's stock reaction was material. PolyMedica's stock price is entirely and completely a function of investor's estimates of the company's incurred criminal and civil liabilities. As a result, the only reasonable conclusion is that investors are buying PolyMedica shares believing that its accounting was one of the potential criminal charges and that the accounting announcement positively impacted the severity or likelihood of the penalties PolyMedica faces. These beliefs are completely wrong. Last week's announcement has no bearing whatsoever on either the on-going proceedings or the severity of the outcomes.

For 2 years PolyMedica wrongly denied the existence of any civil or criminal investigation. The denial continued even after PolyMedica was inexplicably denied listing on the New York Stock Exchange. Finally in August 2001, 13 days before the Federal Bureau of Investigation ("FBI") raid, PolyMedica acknowledged first the existence of an investigation and then that the investigation is criminal. PolyMedica then began claiming that the illegal activities were old news and that it was fully cooperating with the investigation. As a result, investors have been repeatedly lured into buying PolyMedica's stock in anticipation of a settlement. No settlement has occurred. Instead, PolyMedica was forced to disclose the existence of allegations of obstruction of justice.

Contrary to the on-going stock promotion, there is no irregular delay in the PolyMedica investigation. There are no facts in the record to support the belief that there are or that there ever have been any settlement talks to end the prosecution. On the contrary, all available evidence from the Centers for Medicare and Medicaid Services Office of Inspector General, the Department of Justice and the FBI show a consistent 4 year and 3 month record of diligent and effective prosecution of a very serious criminal investigation.

Asensio & Company, Inc. is actively engaged in short sell investments and publishes research on securities it believes are overvalued. Our published work with short-selling transactions is available on the Internet at www.asensio.com.

Asensio & Company, Inc. is not a registered broker-dealer. The material provided in asensio.com is for informational purposes only. No mention of a particular security in asensio.com constitutes a recommendation to buy, sell, or hold that or any other security, or that any particular security, portfolio of securities, transaction or investment strategy is suitable for any specific person. We will not advise you personally concerning the nature, potential, value or suitability of any particular security, portfolio of securities, transaction, investment strategy or other matter. The opinions expressed herein belong to us. We do not guarantee or warrant the adequacy, accuracy, completeness or current state of any information, the suitability or profitability of any particular investment, or the potential value of any investment or informational source. Investments in securities, commodities or futures have inherent risk, and a person takes such risks knowingly and bears full responsibility for his/her own investment research and decisions. We will not be liable
for any loss or injury resulting directly or indirectly from use of asensio.com, whether or not caused in whole or in part by Asensio & Company's negligence or by contingencies beyond Asensio & Company's control.